Blood Advances Study: Preeclampsia Risk in Sickle Cell Disease
American Society of Hematology shared an inviting post on LinkedIn:
“In pregnant women with sickle cell disease, the risk of developing early-onset preeclampsia can be determined by measuring levels of a protein associated with placental function and development, according to research published today in Blood Advances.
Placental growth factor (PlGF) is a protein produced by the placenta that supports the development of blood vessels. Measuring PlGF levels can help assess the risk of preeclampsia, a potentially deadly pregnancy complication that usually arises after 20 weeks and is characterized by high blood pressure and protein in the urine.
Women with sickle cell disease are more than 2.4 times likely to develop preeclampsia during pregnancy when compared to women without this condition. This complication can inhibit growth of the fetus, result in premature birth, and is associated with stroke and potential organ damage in the mother.
New findings provide insight that may help clinicians to anticipate and mitigate adverse pregnancy outcomes.
Read more about this new study.”
Stay up-to-date with the latest advancements in hematology through Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies